Shockwave IVL consistently treats calcium from the “real world” across multiple peripheral vascular beds | Your money

0

SANTA CLARA, Calif., October 6, 2021 (GLOBE NEWSWIRE) – Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of intravascular lithotripsy (IVL) for the treatment of severely calcified cardiovascular disease, announced today that an interim analysis of the Disrupt PAD III Observational Study (OS) showed that IVL is consistently performing well on demanding peripheral vessels, lesions and patients. The study, which is the largest core angiographic laboratory confirmed “real” evidence of IVL in severely calcified peripheral arteries, was presented today in a recent clinical study session at VIVA21.

The key results of the first 752 patients in the interim analysis of the Disrupt PAD III OS included:

IVL consistently demonstrated its ability to safely and effectively modify superficial and deep calcium across multiple vascular beds, lesion types, and in patients with critical limb ischemia (CLI) thrombotic events at any point in time IVL results were comparable to previously reported results from the randomized clinical trial ( RCT) to Disrupt PAD III, which showed minimal procedural complications and a consistent reduction in the diameter of the stricture, more complex calcified lesions

“Patients with severe calcification have traditionally been excluded from endovascular treatment studies, which provides little available evidence to treat this difficult patient population,” said Ehrin J. Armstrong, MD, medical director, Adventist Heart and Vascular Institute, St. Helena , CA. “The Disrupt PAD III OS shows that peripheral IVL perform consistently well in a variety of peripheral vessels, lesions, and subgroups in common clinical situations that physicians encounter on a daily basis.”

The Disrupt PAD III OS is a prospective, multicenter, single-blind study on patients from the “real world” that complements the Disrupt PAD III RCT. The interim analysis looked at the results of the first 752 consecutive patients enrolled in the study from November 2017 to June 2019 at 18 locations worldwide. Of the 852 lesions treated in the iliac, common femoral, superficial femoral, popliteal, and infrapopliteal arteries, 88 percent had moderate / severe calcification with an average calcified length of 127 mm. Use of IVL on these lesions resulted in final residual stenosis of 24 percent, similar to the Disrupt PAD III RCT finding of 22 percent. The patients also experienced minimal procedural complications, with only 0.9 percent and 0.1 percent of patients suffering a final dissection (type DF) or perforations, respectively. In particular, there were no cases of embolization, thrombus, no reflow or abrupt closure.

The Disrupt PAD III OS completed enrollment in June 2021 with a total of 1,373 patients; The analysis of the complete data set will be presented in 2022.

About Shockwave Medical, Inc. Shockwave is focused on developing and commercializing products designed to transform the management of calcified cardiovascular disease. Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sound pressure waves to treat calcified plaque, which the company calls intravascular lithotripsy (IVL). IVL is a minimally invasive, easy to use and safe method to significantly improve patient outcomes. An animation of the IVL process and further information can be found at www.shockwavemedical.com.

Forward-Looking Statements This press release contains statements relating to our expectations, projections, beliefs, and prospects that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some instances, you can identify these statements by using forward-looking words such as “could,” “could,” “will,” “should,” “expect,” “planet,” “anticipate,” “believe,” “estimate,” “project.” “,” Potentially “” or “further” and similar expressions and the negatives of these terms. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates and assumptions, valid only as of the date of their publication and are subject to risks and uncertainties, some of which are currently unknown to us.

Important factors that could cause our actual results and financial condition to differ materially from those expressed in the forward-looking statements include, but are not limited to, the impact of the COVID-19 pandemic on our business, financial results, and liquidity and capitalization on our sales, expenses, supply chain, manufacturing, research and development, clinical trials, and employees; our ability to develop, manufacture, obtain and maintain regulatory approvals for our products, to market and sell them; our expected future growth, including the size and growth potential of the markets for our products; our ability to obtain coverage and reimbursement for procedures performed on our products; our ability to scale our corporate culture; the effects of the development, regulatory approval, effectiveness and commercialization of competing products; the loss of key scientific or management personnel; our ability to develop and maintain our corporate infrastructure, including our internal controls; our financial standing and capital requirements; and our ability to obtain and maintain intellectual property protection for our products and our ability to conduct our business without violating the intellectual property rights of others. These and other factors are discussed in our filings with the Securities and Exchange Commission (SEC), including Part I, Item IA – Risk Factors in our most recent Annual Report on Form 10-K filed with the SEC and on our other regular reports and other reports filed with the SEC. Except to the extent required by law, we undertake no obligation to update these forward-looking statements after the date of this release in order to adapt these statements to actual results or changed expectations

Media contact: Scott Shadiow +1.317.432.9210 [email protected]

Investor Contact: Debbie Kaster [email protected]

Copyright 2021 GlobeNewswire, Inc.


Source link

Share.

Leave A Reply